Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660710 | 0.88 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA3ADORA2ANFKB1 | |
| SCHEMBL7732676 | 0.85 | SLC29A1 (0.55) | SLC29A1P2RX3P2RX2ADORA1ADORA3 | |
| SCHEMBL5364270 | 0.81 | DOT1L (0.59) | ADORA1ADORA3 | |
| SCHEMBL5364283 | 0.81 | DOT1L (0.59) | ADORA1ADORA3 | |
| SCHEMBL5372073 | 0.81 | ADORA3 (0.64) | ADORA1ADORA3ADORA2ADNPH1NFKB1 | |
| SCHEMBL5372080 | 0.81 | ADORA3 (0.64) | ADORA1ADORA3ADORA2ADNPH1NFKB1 | |
| SCHEMBL8079835 | 0.80 | ADORA3 (0.51) | SLC29A1P2RX3P2RX2ADORA1ADORA3 | |
| SCHEMBL5366331 | 0.79 | ADORA3 (0.58) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL5366323 | 0.79 | ADORA3 (0.58) | SLC29A1ADORA1ADORA3ADORA2ATSHR | |
| SCHEMBL6663125 | 0.78 | NT5E (0.53) | ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027363-B1 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2003-06-04 | — | — | EP | claimed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | claimed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | claimed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | claimed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | disclosed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |